# HighLife

> Structural-heart medtech company that raised more than $90 million to advance a U.S. pivotal study and European commercialization.

## Why it is interesting

HighLife has a low-difficulty company query and a material clinical-stage financing that broadens VCT's healthcare coverage.

## Profile

- **Latest funding:** Growth financing — >$90M (€80M) (September 22, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** Not publicly disclosed
- **Stage:** growth
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-09-30
- **Latest funding investors:** Andera Partners, Sofinnova Partners, Supernova Invest, Mérieux Equity Partners

## Key facts

- Sep 22, 2026: >$90M / €80M financing
- Capital supports a U.S. pivotal study and European commercialization

## Funding history

- Growth financing · >$90M (€80M) · September 22, 2026
  Source: https://www.globenewswire.com/news-release/2026/09/22/3365967/0/fr/highlife-l%C3%A8ve-plus-de-90-millions-de-dollars-pour-lancer-son-%C3%A9tude-pivot-aux-%C3%A9tats-unis-et-acc%C3%A9l%C3%A9rer-son-d%C3%A9veloppement-commercial-en-europe.html

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** September 30, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/highlife-medical